XML 66 R30.htm IDEA: XBRL DOCUMENT
v3.19.2

Revenues (Tables) | 6 Months Ended
--- | ---
Jun. 30, 2019
Revenue from Contract with Customer [Abstract] |
Revenues by product | Revenues by product are summarized as follows:
| For the Three Months Ended June 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 869.8 |  |  | $ | 280.4 |  |  | $ | 1,150.2 |  |  | $ | 825.8 |  |  | $ | 261.0 |  |  | $ | 1,086.8 |
Interferon* | 379.7 |  |  | 174.7 |  |  | 554.4 |  |  | 444.7 |  |  | 180.8 |  |  | 625.5 |
TYSABRI | 264.3 |  |  | 211.0 |  |  | 475.3 |  |  | 265.5 |  |  | 201.7 |  |  | 467.2 |
FAMPYRA | — |  |  | 24.1 |  |  | 24.1 |  |  | — |  |  | 23.0 |  |  | 23.0 |
Subtotal: MS product revenues | 1,513.8 |  |  | 690.2 |  |  | 2,204.0 |  |  | 1,536.0 |  |  | 666.5 |  |  | 2,202.5 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 230.6 |  |  | 257.6 |  |  | 488.2 |  |  | 205.9 |  |  | 216.8 |  |  | 422.7 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 120.3 |  |  | 120.3 |  |  | — |  |  | 115.6 |  |  | 115.6 |
IMRALDI | — |  |  | 47.3 |  |  | 47.3 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 16.8 |  |  | 16.8 |  |  | — |  |  | 11.2 |  |  | 11.2 |
Subtotal: Biosimilar product revenues | — |  |  | 184.4 |  |  | 184.4 |  |  | — |  |  | 126.8 |  |  | 126.8 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 3.7 |  |  | 3.7 |  |  | — |  |  | 5.5 |  |  | 5.5 |
Total product revenues | $ | 1,744.4 |  |  | $ | 1,135.9 |  |  | $ | 2,880.3 |  |  | $ | 1,741.9 |  |  | $ | 1,015.6 |  |  | $ | 2,757.5 |
*Interferon includes AVONEX and PLEGRIDY.
| For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018
| United States |  | Rest of World |  | Total |  | United States |  | Rest of World |  | Total
Multiple Sclerosis (MS): |  |  |  |  |  |  |  |  |  |  |
TECFIDERA | $ | 1,587.5 |  |  | $ | 561.5 |  |  | $ | 2,149.0 |  |  | $ | 1,554.7 |  |  | $ | 519.0 |  |  | $ | 2,073.7 |
Interferon* | 707.0 |  |  | 348.3 |  |  | 1,055.3 |  |  | 816.0 |  |  | 359.8 |  |  | 1,175.8 |
TYSABRI | 509.3 |  |  | 426.4 |  |  | 935.7 |  |  | 515.2 |  |  | 414.1 |  |  | 929.3 |
FAMPYRA | — |  |  | 47.0 |  |  | 47.0 |  |  | — |  |  | 47.4 |  |  | 47.4 |
ZINBRYTA | — |  |  | — |  |  | — |  |  | — |  |  | 1.4 |  |  | 1.4 |
Subtotal: MS product revenues | 2,803.8 |  |  | 1,383.2 |  |  | 4,187.0 |  |  | 2,885.9 |  |  | 1,341.7 |  |  | 4,227.6 |
Spinal Muscular Atrophy: |  |  |  |  |  |  |  |  |  |  |
SPINRAZA | 453.9 |  |  | 552.8 |  |  | 1,006.7 |  |  | 393.9 |  |  | 392.7 |  |  | 786.6 |
Biosimilars: |  |  |  |  |  |  |  |  |  |  |
BENEPALI | — |  |  | 244.3 |  |  | 244.3 |  |  | — |  |  | 236.5 |  |  | 236.5 |
IMRALDI | — |  |  | 83.0 |  |  | 83.0 |  |  | — |  |  | — |  |  | — |
FLIXABI | — |  |  | 31.5 |  |  | 31.5 |  |  | — |  |  | 17.8 |  |  | 17.8 |
Subtotal: Biosimilar product revenues | — |  |  | 358.8 |  |  | 358.8 |  |  | — |  |  | 254.3 |  |  | 254.3 |
Other: |  |  |  |  |  |  |  |  |  |  |
FUMADERM | — |  |  | 7.8 |  |  | 7.8 |  |  | — |  |  | 12.5 |  |  | 12.5 |
Total product revenues | $ | 3,257.7 |  |  | $ | 2,302.6 |  |  | $ | 5,560.3 |  |  | $ | 3,279.8 |  |  | $ | 2,001.2 |  |  | $ | 5,281.0 |
*Interferon includes AVONEX and PLEGRIDY.
Analysis of change In reserves | An analysis of the change in reserves for discounts and allowances is summarized as follows:
(In millions) | Discounts |  | Contractual Adjustments |  | Returns |  | Total
Balance, as of December 31, 2018 | $ | 127.8 |  |  | $ | 888.8 |  |  | $ | 34.7 |  |  | $ | 1,051.3 |
Current provisions relating to sales in current year | 308.8 |  |  | 1,391.0 |  |  | 10.6 |  |  | 1,710.4 |
Adjustments relating to prior years | (0.4 | ) |  | (41.9 | ) |  | (0.1 | ) |  | (42.4 | )
Payments/credits relating to sales in current year | (189.6 | ) |  | (827.6 | ) |  | (0.6 | ) |  | (1,017.8 | )
Payments/credits relating to sales in prior years | (121.9 | ) |  | (505.2 | ) |  | (11.9 | ) |  | (639.0 | )
Balance, as of June 30, 2019 | $ | 124.7 |  |  | $ | 905.1 |  |  | $ | 32.7 |  |  | $ | 1,062.5 |
Total reserves included in consolidated balance sheets | The total reserves above, which are included in our condensed consolidated balance sheets, are summarized as follows:
(In millions) | As of June 30, 2019 |  | As of December 31, 2018
Reduction of accounts receivable, net | $ | 199.0 |  |  | $ | 176.6 |
Component of accrued expenses and other | 863.5 |  |  | 874.7 |
Total revenue-related reserves | $ | 1,062.5 |  |  | $ | 1,051.3 |
Revenues from anti-CD20 therapeutic programs | Revenues from anti-CD20 therapeutic programs are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Biogen’s share of pre-tax profits in the U.S. for RITUXAN, RITUXAN HYCELA and GAZYVA | $ | 377.2 |  |  | $ | 359.0 |  |  | $ | 768.0 |  |  | $ | 708.6 |
Other revenues from anti-CD20 therapeutic programs | 199.2 |  |  | 131.4 |  |  | 325.8 |  |  | 225.0 |
Total revenues from anti-CD20 therapeutic programs | $ | 576.4 |  |  | $ | 490.4 |  |  | $ | 1,093.8 |  |  | $ | 933.6 |
Other revenues | Other revenues are summarized as follows:
| For the Three Months Ended June 30, |  | For the Six Months Ended June 30,
(In millions) | 2019 |  | 2018 |  | 2019 |  | 2018
Revenues from collaborative and other relationships: |  |  |  |  |  |  |
(Loss) profit earned under our 50% share of the co-promotion losses on ZINBRYTA in the U.S. with AbbVie | $ | (0.1 | ) |  | $ | (2.5 | ) |  | $ | (0.5 | ) |  | $ | (7.2 | )
Revenues earned under our technical development agreement, manufacturing services agreements and royalty revenues on biosimilar products with Samsung Bioepis | 52.2 |  |  | 14.7 |  |  | 77.0 |  |  | 32.6 |
Other royalty and corporate revenues: |  |  |  |  |  |  |  |  |
Royalty | 2.7 |  |  | 17.3 |  |  | 6.6 |  |  | 27.9 |
Other corporate | 105.2 |  |  | 79.1 |  |  | 369.3 |  |  | 219.7 |
Total other revenues | $ | 160.0 |  |  | $ | 108.6 |  |  | $ | 452.4 |  |  | $ | 273.0 |

X
- Definition Analysis of amount of and change in product revenue reserves. + References No definition available. + Details
Name: | biib_AnalysisOfAmountOfAndChangeInProductRevenueReservesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Other revenues [Table Text Block] + References No definition available. + Details
Name: | biib_OtherrevenuesTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Revenues from anti-CD20 therapeutic programs + References No definition available. + Details
Name: | biib_RevenuesfromantiCD20therapeuticprogramsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Summary of total product revenue reserves included in consolidated balance sheets. + References No definition available. + Details
Name: | biib_SummaryOfProductRevenueReservesIncludedInConsolidatedBalanceSheetsTableTextBlock
Namespace Prefix: | biib_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor. + References Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef -Publisher FASB -Name Accounting Standards Codification -Topic 606 -SubTopic 10 -Section 50 -Paragraph 5 -URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045 + Details
Name: | us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix: | us-gaap_
Data Type: | nonnum:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- References No definition available. + Details
Name: | us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration